Sino Biopharmaceutical's respiratory business reaches dual milestones

Overview

This report focuses on two key developments in Sino Biopharmaceutical's respiratory business: first, the overseas licensing of TQC3721 to AstraZeneca; and second, the expansion of its cooperation with GSK through the introduction of two COPD drugs, Trelegy and Anoro. The report believes these transactions validate the company's ability to generate globally competitive assets through its internal R&D platform and strengthen its commercialization presence in China's COPD treatment matrix.

Core views

The core view is positive: TQC3721 is another Chinese-originated PDE3/4 inhibitor asset to secure cooperation with a major multinational pharmaceutical company following the Hengrui-related transaction, indicating improved Sino Biopharmaceutical BD capabilities; the GSK product portfolio can create synergies with the company's existing respiratory sales network; and raised earnings forecasts and the higher PDE3/4i probability-of-success assumption support the target price increase. However, the report also cautions that the COPD competitive landscape is evolving rapidly, and long-acting or broad-spectrum biologics such as IL-33 and TSLP/IL13 therapies could weaken the differentiation advantage of PDE3/4 inhibitors.

Analysis framework

The report combines an event-driven approach with valuation updates: it first assesses the strategic significance of the AstraZeneca licensing terms and GSK product introduction for the respiratory pipeline and commercial platform, then conducts a non-head-to-head comparison of TQC3721 clinical data with ensifentrine, and finally incorporates the upfront payment, Trelegy/Anoro sales forecasts, and PoLS adjustment into the earnings forecasts and SOTP valuation.

Methodology notes

• Valuation methodsSOTP

  Sum-of-the-parts valuation

  The 12-month target price of HK$8.41 is based on SOTP, including an HK$101.6bn DCF valuation for the innovative pipeline, an HK$50.2bn valuation for generic drugs, and an HK$6.0bn DCF valuation for anlotinib and PD-(L)1.

• Valuation methodsDCF

  Discounted cash flow

  The innovative pipeline and anlotinib/PD-(L)1 segments are valued using DCF to reflect future cash flows and pipeline probability of success.

• Clinical comparisonNon-head-to-head comparison

  Cross-trial efficacy comparison

  The report compares TQC3721's Phase 2 FEV1 improvement data with publicly available ensifentrine data on a non-head-to-head basis, emphasizing differences in formulation convenience and safety.

• Risk adjustmentPoLS

  Probability of success

  Because TQC3721 has secured a global partner, the report raises the PoLS for PDE3/4i from 80% to 100%.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sino Biopharmaceutical (01177.HK)

  Research subject

  Strengths

  Has dual innovative-drug and generic-drug platforms, with cash reserves supporting BD; already has 30+ marketed respiratory products, a 2,000+ dedicated sales team, and broad hospital coverage; the overseas licensing of TQC3721 validates its internal R&D capabilities.

  Weaknesses

  The group's subsidiary resource allocation is complex, and the report remains cautious about R&D execution; some traditional businesses continue to face price pressure from centralized procurement.

  Comparison

  TQC3721's efficacy is broadly comparable to ensifentrine in a non-head-to-head comparison, while the DPI formulation may offer greater convenience than nebulized administration.

  Risks

  Broader price reductions across the generic-drug portfolio, delays in approval of key pipeline products, low returns on R&D investment, and innovative-drug launches below expectations.

• TQC3721

  Core respiratory pipeline asset

  Strengths

  The PDE3/4 inhibitor has entered Phase 3; it has secured a partnership with AstraZeneca for rights outside China; Phase 2 FEV1 improvements indicate comparable efficacy, with no treatment discontinuations reported.

  Weaknesses

  Further clinical and regulatory validation is still required; the DPI version remains in Phase 2, with Phase 1 data expected in 2H26.

  Comparison

  Compared with ensifentrine, efficacy is broadly comparable, while the convenience of the DPI formulation may be a differentiating factor.

  Risks

  Broad-spectrum COPD biologics such as AstraZeneca's tozorakimab and long-acting drugs such as Keymed's CM512 could alter the competitive landscape.

• Trelegy and Anoro

  Introduced GSK COPD commercial products

  Strengths

  Strong global sales base, with combined sales approaching US$5bn in 2025; sales in China remain below Rmb1bn, leaving room for penetration and share gains; can strengthen coverage of acute exacerbation and maintenance treatment.

  Weaknesses

  The introduction period is 5.5 years, creating uncertainty regarding long-term rights and renewal arrangements.

  Comparison

  Complementary to the company's existing COPD portfolio and capable of generating commercial synergies with internally developed pipelines such as TQC3721, TQC2731, and TQH2722.

  Risks

  Intensifying competition in China's COPD market and slower-than-expected rollout or an underperforming reimbursement/pricing environment.

Key data

• AstraZeneca licensing upfront paymentUS$200mnPart of the transaction licensing TQC3721 rights outside China.
• Potential milestone paymentsUp to US$1.7bnIncludes development, regulatory, and commercial milestones, plus tiered sales royalties of up to a double-digit percentage.
• Global sales of Trelegy and AnoroNearly US$5bn combined in 2025Combined current sales in China remain below Rmb1bn, suggesting substantial room for penetration.
• Trelegy and Anoro sales forecastsRmb1.2bn/1.4bn/1.7bnCorresponding to 2026/27/28E, with 2026 reflecting only 4Q sales.
• Earnings forecast adjustments+6.9%/+2.6%/+2.7%Corresponding to 2026/27/28E.
• TQC3721 FEV1 improvement+100mL/+147mLRelative improvement versus placebo at week 4 for the 3mg and 6mg dose groups in Phase 2 data.
• ensifentrine FEV1 improvement+124mLData for first-mover ensifentrine 3mg used by the report for the non-head-to-head comparison.
• Sales platform coverage2,000+ sales representatives, 9,000+ hospitalsThe company's dedicated respiratory sales team and nationwide hospital coverage.
• Target priceHK$8.41Raised from HK$8.18.

Impact & implications

For Sino Biopharmaceutical, the transactions bring near-term revenue and earnings forecast upgrades and increase market recognition of its ability to internationalize innovative drug assets; the introduction of GSK products should accelerate monetization of its respiratory commercial platform and create synergies for internally developed pipelines such as TQC3721, TQC2731, and TQH2722. For investment purposes, the report maintains a Buy rating, viewing the low valuation range, solid earnings growth, and potential for further BD transactions as sources of support.

Risks

• Broader price reductions across the generic-drug portfolio.
• Regulatory approval delays for key pipeline products.
• Misallocation of R&D resources leading to low returns on R&D investment.
• Innovative-drug launches below expectations.
• Rapid changes in the COPD treatment landscape; new mechanisms or long-acting biologics such as IL-33 and TSLP/IL13 therapies could weaken the differentiation of PDE3/4 inhibitors.
• Slower-than-expected penetration or share gains for Trelegy and Anoro in China.

What to watch

• The pace of AstraZeneca's overseas development of TQC3721 and regulatory milestones.
• The expected Phase 1 data readout for the TQC3721 DPI version in 2H26.
• The sales ramp-up of Trelegy and Anoro in China in 4Q26 and 2027.
• Clinical data and commercialization progress for competing COPD assets such as tozorakimab and CM512.
• Whether the company continues to complete large MNC BD transactions.
• The impact of centralized procurement and generic-drug pricing policies on traditional business margins.